SCHEMBL21807481

SCHEMBL21807481

CC(C)(C)OC(=O)N1CCc2c(nc(C(O)CO)nc2Oc2ccc(F)cc2C(F)(F)F)C1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRPC5 Q9UL62 5/20 0.44
TRPC4 Q9UBN4 2/20 0.40
HPGDS O60760 1/20 0.38
MKNK1 Q9BUB5 4/20 0.37
PARP1 P09874 1/20 0.37
TNKS2 Q9H2K2 1/20 0.37
PARP2 Q9UGN5 1/20 0.37
MET P08581 1/20 0.37
MTOR P42345 1/20 0.35
RAF1 P04049 1/20 0.35
BRAF P15056 1/20 0.35
F12 P00748 1/20 0.34
ESR2 Q92731 1/20 0.34
SCN9A Q15858 1/20 0.34
P2RX3 P56373 1/20 0.34
TGM2 P21980 1/20 0.34
NR1H2 P55055 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28567854 0.90 TRPC5 (0.46) TRPC5TRPC4SCN9A
SCHEMBL21807357 0.85 TRPC5 (0.51) TRPC5TRPC4HPGDSMKNK1PARP1
SCHEMBL21807317 0.84 TRPC5 (0.46) TRPC5TRPC4HPGDSMKNK1PARP1
SCHEMBL29329811 0.84 TRPC5 (0.51) TRPC5TRPC4HPGDSMKNK1PARP1
SCHEMBL29329810 0.83 TRPC5 (0.47) TRPC5TRPC4HPGDSMKNK1PARP1
SCHEMBL21807381 0.81 TRPC5 (0.58) TRPC5TRPC4MKNK1METNR1H2
SCHEMBL21807246 0.81 TRPC5 (0.45) TRPC5TRPC4HPGDSMKNK1PARP1
SCHEMBL27124708 0.79 TRPC5 (0.43) TRPC5TRPC4
SCHEMBL21807469 0.78 TRPC5 (0.44) TRPC5TRPC4HPGDSMKNK1PARP1
SCHEMBL31574269 0.78 TRPC5 (0.44) TRPC5TRPC4HPGDSMKNK1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113939295-B Pyridazinones and methods of use thereof 金翅雀生物公司 2025-05-16 CN disclosed
EP-4414365-A1 PYRIDAZINONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2024-08-14 EP disclosed
EP-3852533-B1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO INC (US) 2024-02-28 EP disclosed
EP-3852533-B1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO INC (US) 2024-02-28 EP disclosed
US-20220152031-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. 2022-05-19 US disclosed
US-20220024917-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. 2022-01-27 US disclosed
US-20220024917-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. 2022-01-27 US disclosed
EP-3941475-A1 PYRIDAZINONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2022-01-26 EP disclosed
EP-3852533-A1 PYRIDAZINONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2021-07-28 EP disclosed
US-11046690-B2 Pyridazinones and methods of use thereof GOLDFINCH BIO, INC. (US) 2021-06-29 US disclosed
US-11046690-B2 Pyridazinones and methods of use thereof GOLDFINCH BIO, INC. (US) 2021-06-29 US disclosed
WO-2020191056-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2020-09-24 WO disclosed
WO-2020191056-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2020-09-24 WO disclosed
US-20200283437-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2020-09-10 US disclosed
US-20200283437-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2020-09-10 US disclosed
US-10654850-B2 Pyridazinones and methods of use thereof GOLDFINCH BIO, INC. (US) 2020-05-19 US disclosed
US-20200102301-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2020-04-02 US disclosed
WO-2020061162-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2020-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220024917-A1 PYRIDAZINONES AND METHODS OF USE THEREOF ATP6V1B1, GLS, REN TRPC5 2486/4885TRPC4 3512/4885HPGDS 173/4885
US-20220152031-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GLS, ATP6V1B1, PDXK TRPC5 3626/4885TRPC4 4095/4885HPGDS 210/4885
US-20200102301-A1 PYRIDAZINONES AND METHODS OF USE THEREOF ATP6V1B1, GLS, REN TRPC5 2486/4885TRPC4 3512/4885HPGDS 173/4885
US-11046690-B2 Pyridazinones and methods of use thereof ATP6V1B1, GLS, REN TRPC5 2486/4885TRPC4 3512/4885HPGDS 173/4885
US-20200283437-A1 PYRIDAZINONES AND METHODS OF USE THEREOF ATP6V1B1, GLS, REN TRPC5 2486/4885TRPC4 3512/4885HPGDS 173/4885
US-10654850-B2 Pyridazinones and methods of use thereof ATP6V1B1, GLS, REN TRPC5 2486/4885TRPC4 3512/4885HPGDS 173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.